Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study

BACKGROUND: This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients < 60 and ≥ 60 years of age receiving ustekinumab over 3 years. METHODS: Measures included adverse events (AE), clinical Disease Activity Index for Psoriatic Arthritis (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gossec, Laure, Theander, Elke, Chakravarty, Soumya D., Bergmans, Paul, Lavie, Frederic, Noël, Wim, Sharaf, Mohamed, Siebert, Stefan, Smolen, Josef S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251537/
https://www.ncbi.nlm.nih.gov/pubmed/37296456
http://dx.doi.org/10.1186/s13075-023-03078-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251537/
https://www.ncbi.nlm.nih.gov/pubmed/37296456
http://dx.doi.org/10.1186/s13075-023-03078-8

Ejemplares similares